JP2005521651A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005521651A5 JP2005521651A5 JP2003560008A JP2003560008A JP2005521651A5 JP 2005521651 A5 JP2005521651 A5 JP 2005521651A5 JP 2003560008 A JP2003560008 A JP 2003560008A JP 2003560008 A JP2003560008 A JP 2003560008A JP 2005521651 A5 JP2005521651 A5 JP 2005521651A5
- Authority
- JP
- Japan
- Prior art keywords
- ethyl
- carbazol
- carboxamide
- oxopyrrolidine
- rac
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- -1 α-hydroxyphenylethyl Chemical group 0.000 claims description 25
- 125000000217 alkyl group Chemical group 0.000 claims description 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 5
- UHOVQNZJYSORNB-UHFFFAOYSA-N benzene Chemical group C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims description 4
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 4
- 125000003545 alkoxy group Chemical group 0.000 claims description 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 3
- 125000004663 dialkyl amino group Chemical group 0.000 claims description 2
- 125000002541 furyl group Chemical group 0.000 claims description 2
- 229910052736 halogen Inorganic materials 0.000 claims description 2
- 150000002367 halogens Chemical class 0.000 claims description 2
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims description 2
- 125000004998 naphthylethyl group Chemical group C1(=CC=CC2=CC=CC=C12)CC* 0.000 claims description 2
- 125000004923 naphthylmethyl group Chemical group C1(=CC=CC2=CC=CC=C12)C* 0.000 claims description 2
- 125000000286 phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 claims description 2
- 125000004076 pyridyl group Chemical group 0.000 claims description 2
- 125000002112 pyrrolidino group Chemical group [*]N1C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 claims 14
- 239000003814 drug Substances 0.000 claims 3
- 239000002253 acid Substances 0.000 claims 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
- 229910052739 hydrogen Inorganic materials 0.000 claims 2
- 239000001257 hydrogen Substances 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 239000011780 sodium chloride Substances 0.000 claims 2
- LNBJEVSBTXABJJ-UHFFFAOYSA-N 1-(2,3-dihydro-1H-inden-2-yl)-N-(9-ethylcarbazol-3-yl)-5-oxopyrrolidine-3-carboxamide Chemical compound C1C2=CC=CC=C2CC1N(C(=O)C1)CC1C(=O)NC1=CC=C2N(CC)C3=CC=CC=C3C2=C1 LNBJEVSBTXABJJ-UHFFFAOYSA-N 0.000 claims 1
- JCFURRFIHPXTAX-UHFFFAOYSA-N 1-[(2,4-dimethoxyphenyl)methyl]-N-(9-ethylcarbazol-3-yl)-5-oxopyrrolidine-3-carboxamide Chemical compound C=1C=C2N(CC)C3=CC=CC=C3C2=CC=1NC(=O)C(CC1=O)CN1CC1=CC=C(OC)C=C1OC JCFURRFIHPXTAX-UHFFFAOYSA-N 0.000 claims 1
- PKCVGJGLFSIAFY-UHFFFAOYSA-N 1-[(2-chlorophenyl)methyl]-N-(9-ethylcarbazol-3-yl)-5-oxopyrrolidine-3-carboxamide Chemical compound C=1C=C2N(CC)C3=CC=CC=C3C2=CC=1NC(=O)C(CC1=O)CN1CC1=CC=CC=C1Cl PKCVGJGLFSIAFY-UHFFFAOYSA-N 0.000 claims 1
- DMWSIFMEUPPWNG-UHFFFAOYSA-N 1-[(4-chlorophenyl)methyl]-N-(9-ethylcarbazol-3-yl)-5-oxopyrrolidine-3-carboxamide Chemical compound C=1C=C2N(CC)C3=CC=CC=C3C2=CC=1NC(=O)C(CC1=O)CN1CC1=CC=C(Cl)C=C1 DMWSIFMEUPPWNG-UHFFFAOYSA-N 0.000 claims 1
- IZALGPXWNQXDRV-UHFFFAOYSA-N 1-cycloheptyl-N-(9-ethylcarbazol-3-yl)-5-oxopyrrolidine-3-carboxamide Chemical compound C=1C=C2N(CC)C3=CC=CC=C3C2=CC=1NC(=O)C(CC1=O)CN1C1CCCCCC1 IZALGPXWNQXDRV-UHFFFAOYSA-N 0.000 claims 1
- PHRABVHYUHIYGY-UHFFFAOYSA-N 1-methylnaphthalene Chemical group C1=CC=C2C([CH2])=CC=CC2=C1 PHRABVHYUHIYGY-UHFFFAOYSA-N 0.000 claims 1
- 125000006282 2-chlorobenzyl group Chemical group [H]C1=C([H])C(Cl)=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 claims 1
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 claims 1
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims 1
- 125000004180 3-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(F)=C1[H] 0.000 claims 1
- 125000004207 3-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(OC([H])([H])[H])=C1[H] 0.000 claims 1
- 125000006283 4-chlorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1Cl)C([H])([H])* 0.000 claims 1
- WNWVKZTYMQWFHE-UHFFFAOYSA-N 4-ethylmorpholine Chemical group [CH2]CN1CCOCC1 WNWVKZTYMQWFHE-UHFFFAOYSA-N 0.000 claims 1
- 125000004861 4-isopropyl phenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
- 206010003246 Arthritis Diseases 0.000 claims 1
- 206010012601 Diabetes mellitus Diseases 0.000 claims 1
- DAYAJPHIZWNGSX-UHFFFAOYSA-N N-(9-ethylcarbazol-3-yl)-1-(2-hydroxy-2-phenylethyl)-5-oxopyrrolidine-3-carboxamide Chemical compound C=1C=C2N(CC)C3=CC=CC=C3C2=CC=1NC(=O)C(CC1=O)CN1CC(O)C1=CC=CC=C1 DAYAJPHIZWNGSX-UHFFFAOYSA-N 0.000 claims 1
- FHRUHJMHXYMPMS-UHFFFAOYSA-N N-(9-ethylcarbazol-3-yl)-1-(3-fluorophenyl)-5-oxopyrrolidine-3-carboxamide Chemical compound C=1C=C2N(CC)C3=CC=CC=C3C2=CC=1NC(=O)C(CC1=O)CN1C1=CC=CC(F)=C1 FHRUHJMHXYMPMS-UHFFFAOYSA-N 0.000 claims 1
- SOOVNANLZQHFLS-UHFFFAOYSA-N N-(9-ethylcarbazol-3-yl)-1-(4-methylphenyl)-5-oxopyrrolidine-3-carboxamide Chemical compound C=1C=C2N(CC)C3=CC=CC=C3C2=CC=1NC(=O)C(CC1=O)CN1C1=CC=C(C)C=C1 SOOVNANLZQHFLS-UHFFFAOYSA-N 0.000 claims 1
- INAKQXVSGVWGFL-UHFFFAOYSA-N N-(9-ethylcarbazol-3-yl)-1-(5-methoxy-2-methylphenyl)-5-oxopyrrolidine-3-carboxamide Chemical compound C=1C=C2N(CC)C3=CC=CC=C3C2=CC=1NC(=O)C(CC1=O)CN1C1=CC(OC)=CC=C1C INAKQXVSGVWGFL-UHFFFAOYSA-N 0.000 claims 1
- ZCNQQHNHLQDKSH-UHFFFAOYSA-N N-(9-ethylcarbazol-3-yl)-1-(furan-2-ylmethyl)-5-oxopyrrolidine-3-carboxamide Chemical compound C=1C=C2N(CC)C3=CC=CC=C3C2=CC=1NC(=O)C(CC1=O)CN1CC1=CC=CO1 ZCNQQHNHLQDKSH-UHFFFAOYSA-N 0.000 claims 1
- ZUOGOMATEORWQP-UHFFFAOYSA-N N-(9-ethylcarbazol-3-yl)-5-oxo-1-(2-propan-2-ylphenyl)pyrrolidine-3-carboxamide Chemical compound C=1C=C2N(CC)C3=CC=CC=C3C2=CC=1NC(=O)C(CC1=O)CN1C1=CC=CC=C1C(C)C ZUOGOMATEORWQP-UHFFFAOYSA-N 0.000 claims 1
- ZHHQKDANPFTHME-UHFFFAOYSA-N N-(9-ethylcarbazol-3-yl)-5-oxo-1-(4-propan-2-ylphenyl)pyrrolidine-3-carboxamide Chemical compound C=1C=C2N(CC)C3=CC=CC=C3C2=CC=1NC(=O)C(CC1=O)CN1C1=CC=C(C(C)C)C=C1 ZHHQKDANPFTHME-UHFFFAOYSA-N 0.000 claims 1
- ZZVBAJXEDCJVTK-UHFFFAOYSA-N N-(9-ethylcarbazol-3-yl)-5-oxo-1-(thiophen-2-ylmethyl)pyrrolidine-3-carboxamide Chemical compound C=1C=C2N(CC)C3=CC=CC=C3C2=CC=1NC(=O)C(CC1=O)CN1CC1=CC=CS1 ZZVBAJXEDCJVTK-UHFFFAOYSA-N 0.000 claims 1
- ZCKRHWXFISGALU-UHFFFAOYSA-N N-(9-ethylcarbazol-3-yl)-5-oxo-1-phenylpyrrolidine-3-carboxamide Chemical compound C=1C=C2N(CC)C3=CC=CC=C3C2=CC=1NC(=O)C(CC1=O)CN1C1=CC=CC=C1 ZCKRHWXFISGALU-UHFFFAOYSA-N 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- XYVMBSCIEDOIJQ-UHFFFAOYSA-N Squamolone Chemical compound NC(=O)N1CCCC1=O XYVMBSCIEDOIJQ-UHFFFAOYSA-N 0.000 claims 1
- 150000007513 acids Chemical class 0.000 claims 1
- 150000001412 amines Chemical class 0.000 claims 1
- 150000007514 bases Chemical class 0.000 claims 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 1
- 235000014632 disordered eating Nutrition 0.000 claims 1
- 239000002552 dosage form Substances 0.000 claims 1
- 201000006180 eating disease Diseases 0.000 claims 1
- 150000002148 esters Chemical class 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 125000001037 p-tolyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- NYCVCXMSZNOGDH-UHFFFAOYSA-N pyrrolidine-1-carboxylic acid Chemical compound OC(=O)N1CCCC1 NYCVCXMSZNOGDH-UHFFFAOYSA-N 0.000 claims 1
- 239000012453 solvate Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CH23812001 | 2001-12-31 | ||
| CH0200429 | 2002-08-05 | ||
| PCT/CH2002/000725 WO2003059905A1 (de) | 2001-12-31 | 2002-12-27 | Pyrrolidon-carboxamide |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005521651A JP2005521651A (ja) | 2005-07-21 |
| JP2005521651A5 true JP2005521651A5 (ko) | 2009-11-26 |
Family
ID=25705687
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003560008A Pending JP2005521651A (ja) | 2001-12-31 | 2002-12-27 | ピロリドンカルボキサミド類 |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP1463724A1 (ko) |
| JP (1) | JP2005521651A (ko) |
| KR (1) | KR20040072697A (ko) |
| CN (1) | CN100534990C (ko) |
| AU (1) | AU2002350366A1 (ko) |
| CA (1) | CA2471620A1 (ko) |
| MX (1) | MXPA04006458A (ko) |
| WO (1) | WO2003059905A1 (ko) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0319151D0 (en) * | 2003-08-14 | 2003-09-17 | Glaxo Group Ltd | Novel compounds |
| US20080125403A1 (en) | 2004-04-02 | 2008-05-29 | Merck & Co., Inc. | Method of Treating Men with Metabolic and Anthropometric Disorders |
| US8415354B2 (en) | 2004-04-29 | 2013-04-09 | Abbott Laboratories | Methods of use of inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme |
| US7880001B2 (en) | 2004-04-29 | 2011-02-01 | Abbott Laboratories | Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme |
| US20100222316A1 (en) | 2004-04-29 | 2010-09-02 | Abbott Laboratories | Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme |
| US8198331B2 (en) | 2005-01-05 | 2012-06-12 | Abbott Laboratories | Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme |
| US7511175B2 (en) | 2005-01-05 | 2009-03-31 | Abbott Laboratories | Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme |
| US20090192198A1 (en) | 2005-01-05 | 2009-07-30 | Abbott Laboratories | Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme |
| JPWO2006104280A1 (ja) * | 2005-03-31 | 2008-09-11 | 武田薬品工業株式会社 | 糖尿病の予防・治療剤 |
| JP4726243B2 (ja) * | 2005-08-09 | 2011-07-20 | 第一三共株式会社 | 新規セルコスポラミド誘導体 |
| KR20080033367A (ko) * | 2005-08-09 | 2008-04-16 | 다이이찌 산쿄 가부시키가이샤 | 신규 세르코스포라미드 유도체 |
| US7435833B2 (en) | 2006-04-07 | 2008-10-14 | Abbott Laboratories | Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme |
| JP5736098B2 (ja) | 2007-08-21 | 2015-06-17 | アッヴィ・インコーポレイテッド | 中枢神経系障害を治療するための医薬組成物 |
| GB0815781D0 (en) * | 2008-08-29 | 2008-10-08 | Xention Ltd | Novel potassium channel blockers |
| EP2480531B1 (en) * | 2009-09-21 | 2014-11-05 | ChemoCentryx, Inc. | Pyrrolidinone carboxamide derivatives as chemerin-r (chemr23) modulators |
| CN102827056B (zh) * | 2012-09-03 | 2014-07-23 | 华东理工大学 | N-芳基取代吡咯烷酮衍生物及其用途 |
| AU2015239020A1 (en) * | 2014-04-04 | 2016-10-13 | Sanofi | Substituted indanone compounds as GPR119 modulators for the treatment of diabetes, obesity, dyslipidemia and related disorders |
| US10968176B2 (en) | 2014-09-14 | 2021-04-06 | Nanosynthons Llc | Pyrrolidone derivatives, oligomers and polymers |
| EP3194365A4 (en) * | 2014-09-14 | 2018-04-25 | Nanosynthons LLC | Pyrrolidone derivatives, oligomers and polymers |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB856452A (en) * | 1957-06-27 | 1960-12-14 | Bayer Ag | Protective agents against textile pests, mould and bacteria |
| US5281612A (en) * | 1982-09-09 | 1994-01-25 | Warner-Lambert Company | Naphthyridine antibacterial agents |
| ES2087097T3 (es) * | 1989-04-19 | 1996-07-16 | Otsuka Pharma Co Ltd | Derivados de acidos fenilcarboxilicos que contienen un heterociclo. |
| US6387932B1 (en) * | 1999-06-25 | 2002-05-14 | Merck & Co., Inc. | Somatostatin agonists |
| AU6000900A (en) * | 1999-07-23 | 2001-02-13 | Astrazeneca Uk Limited | Carbazole derivatives and their use as neuropeptide y5 receptor ligands |
| GB0010757D0 (en) * | 2000-05-05 | 2000-06-28 | Astrazeneca Ab | Chemical compounds |
-
2002
- 2002-12-27 KR KR10-2004-7010431A patent/KR20040072697A/ko not_active Application Discontinuation
- 2002-12-27 MX MXPA04006458A patent/MXPA04006458A/es unknown
- 2002-12-27 CN CNB028265483A patent/CN100534990C/zh not_active Expired - Fee Related
- 2002-12-27 JP JP2003560008A patent/JP2005521651A/ja active Pending
- 2002-12-27 AU AU2002350366A patent/AU2002350366A1/en not_active Abandoned
- 2002-12-27 EP EP02785006A patent/EP1463724A1/de not_active Withdrawn
- 2002-12-27 WO PCT/CH2002/000725 patent/WO2003059905A1/de active Application Filing
- 2002-12-27 CA CA002471620A patent/CA2471620A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005521651A5 (ko) | ||
| TW386081B (en) | Opioid compounds | |
| US6930185B2 (en) | Melanin-concentrating hormone antagonist | |
| JP3664492B2 (ja) | タチキニン ｎｋ▲下３▼ 受容体アンタゴニストとしてのキノリン誘導体 | |
| JPS584752A (ja) | カルボキシアミド誘導体及びその製造法 | |
| US20050209213A1 (en) | Quinoline compound | |
| WO2002100844A2 (en) | Hiv protease inhibitors, compositions containing the same, their pharmaceutical uses and materials for their synthesis | |
| JP2000504677A (ja) | ５ｈｔ７レセプター・アンタゴニスト用のスルホンアミド誘導体 | |
| JPH07503247A (ja) | オピオイドジアリールメチルピペラジンおよびピペリジン | |
| EP1227090A1 (en) | Amine derivatives | |
| SK280906B6 (sk) | Použitie tetrahydrokarbazolových derivátov | |
| CS228532B2 (en) | Production method of phenylpiperazine derivative | |
| JPH11505237A (ja) | ジアリールジアミン誘導体およびそれらのデルタオピオイド（アント）−アゴニストとしての使用 | |
| MXPA04002338A (es) | Derivados de carbazol y su uso como antagonistas receptores del npy5. | |
| BRPI0413393A (pt) | fexofenadina, composição farmaceuticamente aceitável, método de tratamento antihistamìnico, composição, processo para preparar fexofenadina e uso de fexofenadina | |
| CN1450898A (zh) | 用于治疗纤维肌痛和慢性疲劳综合症的化合物 | |
| JP2005500370A5 (ko) | ||
| CA2438854A1 (en) | Method of preparing non-hydrated fexofenadine hydrochloride and novel crystalline form obtainable by this method | |
| JP2011528030A5 (ko) | ||
| JPH10506111A (ja) | タモキシフェンおよびタモキシフェン類縁体の向子宮効果を削減する方法 | |
| EP2060563A1 (en) | Cyclic aminoalkylcarboxamide derivative | |
| CN1128030A (zh) | 具有中枢神经系统活性的杂环胺 | |
| CN1060773C (zh) | 用作精神抑制药的3－β－氨基氮杂双环辛烷或壬烷的萘甲酰胺衍生物 | |
| JPS6257606B2 (ko) | ||
| US4755520A (en) | Spartein compounds, their preparation and use |